| Natriuretic peptide–based screening and collaborative care for heart failure: the STOP-HF randomized trial M Ledwidge, J Gallagher, C Conlon, E Tallon, E O’Connell, I Dawkins, ... Jama 310 (1), 66-74, 2013 | 632 | 2013 |
| Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction R Martos, J Baugh, M Ledwidge, C O’Loughlin, C Conlon, A Patle, ... Circulation 115 (7), 888-895, 2007 | 622 | 2007 |
| Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype CJ Watson, P Collier, I Tea, R Neary, JA Watson, C Robinson, D Phelan, ... Human molecular genetics 23 (8), 2176-2188, 2014 | 292 | 2014 |
| Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial P Ponikowski, SD Anker, J Szachniewicz, D Okonko, M Ledwidge, ... Journal of the American College of Cardiology 49 (7), 753-762, 2007 | 282 | 2007 |
| Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? P Collier, CJ Watson, V Voon, D Phelan, A Jan, G Mak, R Martos, ... European journal of heart failure 13 (10), 1087-1095, 2011 | 250 | 2011 |
| MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure CJ Watson, SK Gupta, E O'Connell, S Thum, N Glezeva, J Fendrich, ... European journal of heart failure 17 (4), 405-415, 2015 | 227 | 2015 |
| Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis? J Lewin, M Ledwidge, C O'Loughlin, C McNally, K McDonald European journal of heart failure 7 (6), 953-957, 2005 | 219 | 2005 |
| Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care K McDonald, M Ledwidge, J Cahill, P Quigley, B Maurer, B Travers, ... Journal of cardiac failure 8 (3), 142-148, 2002 | 190 | 2002 |
| Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover R Martos, J Baugh, M Ledwidge, C O'Loughlin, NF Murphy, C Conlon, ... European journal of heart failure 11 (2), 191-197, 2009 | 172 | 2009 |
| The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients R O'Hanlon, P O'Shea, M Ledwidge, C O'Loughlin, S Lange, C Conlon, ... Journal of cardiac failure 13 (1), 50-55, 2007 | 171 | 2007 |
| Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone GJ Mak, MT Ledwidge, CJ Watson, DM Phelan, IR Dawkins, NF Murphy, ... Journal of the American College of Cardiology 54 (18), 1674-1682, 2009 | 162 | 2009 |
| Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability B Travers, C O'Loughlin, NF Murphy, M Ryder, C Conlon, M Ledwidge, ... Journal of cardiac failure 13 (2), 128-132, 2007 | 146 | 2007 |
| Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease … N Glezeva, V Voon, C Watson, S Horgan, K McDonald, M Ledwidge, ... Journal of cardiac failure 21 (2), 167-177, 2015 | 145 | 2015 |
| Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high‐risk, elderly heart failure population: the potential contributions … K McDonald, M Ledwidge, J Cahill, J Kelly, P Quigley, B Maurer, F Begley, ... European journal of heart failure 3 (2), 209-215, 2001 | 120 | 2001 |
| Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance: NO and MMP-9 interactions S O'Sullivan, C Medina, M Ledwidge, MW Radomski, JF Gilmer Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1843 (3), 603-617, 2014 | 119 | 2014 |
| Is multidisciplinary care of heart failure cost‐beneficial when combined with optimal medical care? M Ledwidge, M Barry, J Cahill, E Ryan, B Maurer, M Ryder, B Travers, ... European journal of heart failure 5 (3), 381-389, 2003 | 95 | 2003 |
| Getting to the heart of cardiac remodeling; how collagen subtypes may contribute to phenotype P Collier, CJ Watson, MH Van Es, D Phelan, C McGorrian, M Tolan, ... Journal of molecular and cellular cardiology 52 (1), 148-153, 2012 | 93 | 2012 |
| Proteomic analysis of coronary sinus serum reveals leucine-rich α2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure CJ Watson, MT Ledwidge, D Phelan, P Collier, JC Byrne, MJ Dunn, ... Circulation: Heart Failure 4 (2), 188-197, 2011 | 92 | 2011 |
| Effects of surface active characteristics and solid state forms on the pH solubility profiles of drug–salt systems MT Ledwidge, OI Corrigan International journal of pharmaceutics 174 (1-2), 187-200, 1998 | 90 | 1998 |
| Epigenetic therapy for the treatment of hypertension-induced cardiac hypertrophy and fibrosis CJ Watson, S Horgan, R Neary, N Glezeva, I Tea, N Corrigan, ... Journal of cardiovascular pharmacology and therapeutics 21 (1), 127-137, 2016 | 88 | 2016 |
Joe GallagherDept of General Practice, University College DublinAdresse e-mail validée de ucd.ie
